MedTrace Logo

Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers

NCT03542916 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2018-05-31

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics and safety after a single subcutaneous or intravenous administration of CJ-40001 and NESP® in healthy male volunteers.

Conditions

  • Healthy Subjects

Interventions

DRUG

CJ-40001 60ug

CJ-40001 60ug SC, IV injection

DRUG

NESP 60ug

NESP 60ug SC, IV injection

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-11-30
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542916 on ClinicalTrials.gov